Full Breakdown
Supreme Court Rejects Liability of Generic Drugmaker in Vascepa Patent Dispute
6/6/2026, 4:45:28 AM
Unanimous Ruling Overturns Federal Circuit Decision
On June 4 2026 the U.S. Supreme Court issued a 9-0 opinion authored by Justice Ketanji Brown Jackson, holding that Hikma Pharmaceuticals USA cannot be liable for patent infringement based on doctors’ or pharmacists’ decisions to use its generic version of Vascepa. The Court rejected Amarin Pharma’s claim that Hikma’s label, press releases, and website “actively induced” infringement of Amarin’s cardiovascular-risk (CV) patents. The decision reversed the Federal Circuit’s reversal of a Delaware district-court dismissal.
Legal Context: Patents, Skinny Labels, and Hatch-Waxman
Vascepa is protected by patents covering both its active ingredient and specific therapeutic uses. Under the Hatch-Waxman framework, a “skinny label” permits a generic to be marketed for non-patented indications while omitting patented uses. The FDA approved Hikma’s generic Vascepa solely for severe hypertriglyceridemia (SH indication) and required a skinny label that excluded the less-severe, patented CV indication. Amarin argued that the generic’s broader therapeutic description could steer physicians toward the patented use.
Principal Parties
- Hikma Pharmaceuticals USA – London-based generic manufacturer of Vascepa.
- Amarin Pharma – Irish-American biopharmaceutical company, sole owner of Vascepa’s brand-name product.
- Justice Ketanji Brown Jackson – Author of the unanimous Supreme Court opinion.
- U.S. Food and Drug Administration – Issuer of the skinny-label approval.
- PhRMA – Trade group representing pharmaceutical innovators.
- Campaign for Sustainable Rx Pricing – Advocacy coalition including Blue Cross/Blue Shield, CVS Health, Kaiser Permanent, and AARP.
Financial and Market Stakes
Amarin reported $213.6 million in Vascepa sales for 2025. Hikma and industry advocates contend that generic drugs have saved patients and insurers an estimated $2.9 trillion over the past decade, underscoring the economic impact of preserving the skinny-label pathway for lower-cost competition.
Official Statements
Hikma’s general counsel Sam Park thanked the Court for “unanimously upholding” the company’s right to supply affordable generics. Amarin issued a statement expressing “deep disappointment” and indicated it is reviewing further options. The Trump administration, which backed Hikma’s appeal, highlighted the decision’s potential to keep drug prices low. PhRMA warned that the ruling could disturb the balance intended by Hatch-Waxman, while the Campaign for Sustainable Rx Pricing praised the decision as a restoration of certainty for generic entry.
Criticism and Industry Concerns
PhRMA’s spokesperson Alex Schriver argued that the judgment may weaken incentives to protect patented uses, a cornerstone of research investment. Critics note that allowing generic manufacturers to avoid liability for labeling that broadly describes therapeutic categories could blur the line between permissible description and encouragement of infringement. Amarin’s brief emphasized that Hikma’s conduct was atypical, pointing out that Hikma had not sued seven other firms producing generic Vascepa.
Verbatim Quotes
- “We decline to put generics manufacturers between a rock and a hard place by turning adherence to the law and industry standards into building blocks for illegal conduct.” — Justice Ketanji Brown Jackson
- “The central question is whether Amarin plausibly alleged that Hikma actively encouraged infringing uses, not merely whether doctors could plausibly read the alleged statements as instructions to infringe,” — Justice Ketanji Brown Jackson
- “Skinny labeling under Hatch-Waxman was designed to let generics enter the market for non-patented uses, not as a free pass to promote patented ones,” — Alex Schriver, PhRMA spokesperson
- “helps restore certainty to the skinny-label pathway and will encourage more lower-cost generic competition to enter the market more quickly.” — Lauren Aronson, Campaign for Sustainable Rx Pricing
- “unanimously upheld Hikma's right to continue providing millions of American patients with safe, affordable, high-quality generic medicines.” — Sam Park, General Counsel, Hikma Pharmaceuticals USA
Future Outlook
Amarin has said it is evaluating next steps, while industry observers expect the ruling to accelerate generic introductions using skinny labels across other therapeutic areas.
